Radiopharmaceutical reimbursement rates
- PMID: 18523217
- DOI: 10.1001/jama.299.21.2512-c
Radiopharmaceutical reimbursement rates
Comment on
-
Phase 3 trials suggest ways to improve current hematologic cancer therapies.JAMA. 2008 Feb 6;299(5):510-2. doi: 10.1001/jama.299.5.510. JAMA. 2008. PMID: 18252877 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
